131 related articles for article (PubMed ID: 22824148)
1. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma.
Qiu MH; Qian YM; Zhao XL; Wang SM; Feng XJ; Chen XF; Zhang SH
Pathol Res Pract; 2012 Sep; 208(9):541-8. PubMed ID: 22824148
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic significance of centromere protein A in human lung adenocarcinoma.
Wu Q; Qian YM; Zhao XL; Wang SM; Feng XJ; Chen XF; Zhang SH
Lung Cancer; 2012 Aug; 77(2):407-14. PubMed ID: 22542705
[TBL] [Abstract][Full Text] [Related]
3. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients.
Kato T; Daigo Y; Aragaki M; Ishikawa K; Sato M; Kondo S; Kaji M
Lung Cancer; 2011 Oct; 74(1):124-31. PubMed ID: 21376419
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
[TBL] [Abstract][Full Text] [Related]
6. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
[TBL] [Abstract][Full Text] [Related]
7. Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Yamashita S; Chujo M; Tokuishi K; Anami K; Miyawaki M; Yamamoto S; Kawahara K
J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1303-8. PubMed ID: 19818968
[TBL] [Abstract][Full Text] [Related]
8. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma.
Xu HT; Ma L; Qi FJ; Liu Y; Yu JH; Dai SD; Zhu JJ; Wang EH
Pathol Int; 2006 Jul; 56(7):375-80. PubMed ID: 16792546
[TBL] [Abstract][Full Text] [Related]
9. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
10. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
Shah A; Swain WA; Richardson D; Edwards J; Stewart DJ; Richardson CM; Swinson DE; Patel D; Jones JL; O'Byrne KJ
Clin Cancer Res; 2005 Apr; 11(8):2930-6. PubMed ID: 15837744
[TBL] [Abstract][Full Text] [Related]
11. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer.
Shimizu K; Yoshida J; Nagai K; Nishimura M; Ishii G; Morishita Y; Nishiwaki Y
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):160-5. PubMed ID: 15999057
[TBL] [Abstract][Full Text] [Related]
12. Expression of the transient receptor potential channel c3 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.
Saito H; Minamiya Y; Watanabe H; Takahashi N; Ito M; Toda H; Konno H; Mitsui M; Motoyama S; Ogawa J
Ann Surg Oncol; 2011 Nov; 18(12):3377-83. PubMed ID: 21603869
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.
Wolf G; Elez R; Doermer A; Holtrich U; Ackermann H; Stutte HJ; Altmannsberger HM; Rübsamen-Waigmann H; Strebhardt K
Oncogene; 1997 Feb; 14(5):543-9. PubMed ID: 9053852
[TBL] [Abstract][Full Text] [Related]
14. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
15. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
Clin Lung Cancer; 2010 Mar; 11(2):114-9. PubMed ID: 20199977
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Achiwa H; Yatabe Y; Hida T; Kuroishi T; Kozaki K; Nakamura S; Ogawa M; Sugiura T; Mitsudomi T; Takahashi T
Clin Cancer Res; 1999 May; 5(5):1001-5. PubMed ID: 10353732
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma.
Kim JM; Kang DW; Long LZ; Huang SM; Yeo MK; Yi ES; Kim KH
Hum Pathol; 2011 Mar; 42(3):315-23. PubMed ID: 21190720
[TBL] [Abstract][Full Text] [Related]
18. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin D as a potential prognostic marker for lung adenocarcinoma.
Mimae T; Tsuta K; Maeshima AM; Okada M; Asamura H; Kondo T; Tsuda H
Pathol Res Pract; 2012 Sep; 208(9):534-40. PubMed ID: 22824147
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma.
Narahashi T; Niki T; Wang T; Goto A; Matsubara D; Funata N; Fukayama M
Histopathology; 2006 Oct; 49(4):349-57. PubMed ID: 16978197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
